Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name MEG3
   Synonyms MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1
   Region GRCh38_14:100779410-100861031    Sequence
   Ensembl ENSG00000214548
   RefSeq NR_002766
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name hepatocellular carcinoma
   ICD-0-3 C22.0  M8170/3
   Methods qPCR, MSP-PCR, Western blot, RIP, Flow cytometry assay, MTT assay etc.
   Sample cell lines (HepG2, Huh-7, HEK293)
   Expression Pattern down-regulated
   Function Description

The methylation status of MEG3 promoter may lead to downregulation of MEG3 expression in HepG2 cells. Both adenosine and 5-Aza-CdR increased MEG3 mRNA expression and the CpG island of MEG3 gene in HepG2 cells was typical hypermethylation. Ectopic expression of MEG3 inhibited hepatoma cell growth in a time-dependent manner, resulted in cell cycle arrest and induced apoptosis. Ectopic expression of MEG3 increased p53, caspase-3 mRNA and protein levels, decreased MDM2 and cyclin D1 mRNA and protein levels, as well as ILF3 protein expression in HepG2 cells.

   Pubmed ID 26647875
   Year 2016
   Title The mechanism of adenosine-mediated activation of lncRNA MEG3 and its antitumor effects in human hepatoma cells.
   External Links
   Links for  MEG3 GenBank       HGNC       lncrnadb       Noncode
   Links for  hepatocellular carcinoma Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.